Phase 2 trial of erlotinib with or without PF-3512676 (CPG 7909, a Toll-like receptor 9 agonist) in patients with advanced recurrent EGFR-positive non-small cell lung cancer

Cancer Biology and Therapy

Volumn 14, Issue 7, 2013, Pages 557-563

  Belani, Chandra P ^a   Nemunaitis, John J ^b   Chachoua, Abraham ^c   Eisenberg, Peter D ^d   Raez, Luiz E ^e   Cuevas, J Daniel ^f   Mather, Cecile B ^g   Benner, Rebecca J ^g   Meech, Sandra J ^g  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b MEDICAL CITY DALLAS HOSPITAL   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Clinical Research   (United States)

^e FLORIDA INTERNATIONAL UNIVERSITY   (United States)

^f St Louis Cancer Care   (United States)

^g PFIZER INC   (United States)

Author keywords

Carcinoma; EGFR; Epidermal growth factor; Erlotinib; Non small cell lung cancer; PF 3512676; Receptor; Toll like receptor 9

Indexed keywords

AGATOLIMOD; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB;

ABNORMAL RESPIRATORY SOUND; ACNE; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTHRALGIA; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DECREASED APPETITE; DEHYDRATION; DERMATITIS; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DRY SKIN; DYSPNEA; FATIGUE; FEMALE; FLU LIKE SYNDROME; HEMOPTYSIS; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; IMMUNOPATHOLOGY; INJECTION SITE REACTION; LIMB PAIN; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL PAIN; NAUSEA; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; RECURRENT CANCER; SIDE EFFECT; THORAX PAIN; TREATMENT FAILURE; URINARY TRACT INFECTION; VOMITING; WEIGHT REDUCTION;

CARCINOMA; EGFR; EPIDERMAL GROWTH FACTOR; ERLOTINIB; NON-SMALL CELL LUNG CANCER; PF-3512676; RECEPTOR; TOLL-LIKE RECEPTOR 9;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; OLIGODEOXYRIBONUCLEOTIDES; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TOLL-LIKE RECEPTOR 9;

EID: 84881121899     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.24598     Document Type: Article

References (22)

1. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al.; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123-32; PMID:16014882; http://dx.doi.org/10.1056/NEJMoa050753
2. Ray M, Salgia R, Vokes EE. The role of EGFR inhibition in the treatment of non-small cell lung cancer. Oncologist 2009; 14: 1116-30; PMID:19892771; http://dx.doi.org/10.1634/theoncologist.2009-0054
3. Krieg AM. Development of TLR9 agonists for cancer therapy. J Clin Invest 2007; 117: 1184-94; PMID:17476348; http://dx.doi.org/10.1172/JCI31414
4. Krieg AM. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene 2008; 27: 161-7; PMID:18176597; http://dx.doi.org/10.1038/sj. onc.1210911
5. Pashenkov M, Goëss G, Wagner C, Hörmann M, Jandl T, Moser A, et al. Phase II trial of a Toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J Clin Oncol 2006; 24: 5716-24; PMID:17179105; http://dx.doi.org/10.1200/JCO.2006.07.9129
6. Kim YH, Girardi M, Duvic M, Kuzel T, Link BK, Pinter-Brown L, et al. Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma. J Am Acad Dermatol 2010; 63: 975-83; PMID:20888065; http://dx.doi.org/10.1016/j.jaad.2009. 12.052
7. Thompson JA, Kuzel T, Drucker BJ, Urba WJ, Bukowski RM. Safety and efficacy of PF-3512676 for the treatment of stage IV renal cell carcinoma: an openlabel, multicenter phase I/II study. Clin Genitourin Cancer 2009; 7: E58-65; PMID:19815483; http://dx.doi.org/10.3816/CGC.2009.n.025
8. Leonard JP, Link BK, Emmanouilides C, Gregory SA, Weisdorf D, Andrey J, et al. Phase I trial of Toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma. Clin Cancer Res 2007; 13: 6168-74; PMID:17947483; http://dx.doi.org/10.1158/1078-0432.CCR-07-0815
9. Manegold C, Gravenor D, Woytowitz D, Mezger J, Hirsh V, Albert G, et al. Randomized phase II trial of a Toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage nonsmall- cell lung cancer. J Clin Oncol 2008; 26: 3979-86; PMID:18711188; http://dx.doi.org/10.1200/JCO.2007.12. 5807
10. Hirsh V, Paz-Ares L, Boyer M, Rosell R, Middleton G, Eberhardt WE, et al. Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 (Toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 2011; 29: 2667-74; PMID:21632509; http://dx.doi.org/10.1200/JCO.2010.32.8971
11. Manegold C, van Zandwijk N, Szczesna A, Zatloukal P, Au JSK, Blasinska-Morawiec M, et al. A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer. Ann Oncol 2012; 23: 72-7; PMID:21464154; http://dx.doi.org/10.1093/annonc/mdr030
12. Belani CP, Nemunaitis JJ, Chachoua A, Eisenberg PD, Raez LE, Cuevas JD, et al. Randomized phase II trial of erlotinib with or without PF-3512676 (CPG 7909, a Toll-like receptor 9 [TLR9] agonist) in patients with advanced recurrent epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer (NSCLC). Presented at: 14th Annual World Conference on Lung Cancer (WCLC) of the International Association for the Study of Lung Cancer (IASLC); July 3-7, 2011; Amsterdam, The Netherlands. Abstract 1167.
13. U.S. National Institutes of Health. 2nd line erlotinib treatment with (out) chemotherapy of advanced non small cell lung cancer (NSCLC) (NVALT10) (NCT00835471). Available at: http://www.clinicaltrials. gov/ct2/show/ NCT00835471?term=erlotinib&recr =Open&rank=13term=erlotinib&recr= Open&rank=3. Accessed December 3, 2012.
14. U.S. National Institutes of Health. Erlotinib and docetaxel in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of one chemotherapy regimen (NCT00908336). Available at: http://www.clinicaltrials.gov/ct2/show/NCT00908 336?term=erlotinib&recr= Open&rank=21. Accessed December 3, 2012.
15. U.S. National Institutes of Health. ARQ 197 plus erlotinib versus placebo plus erlotinib for the treatment of non-squamous, non-small-cell lung cancer (NCT01244191). Available at: http://www.clinicaltrials. gov/ct2/show/ NCT01244191?term=erlotinib&recr =Open&rank=27. Accessed December 3, 2012.
16. U.S. National Institutes of Health. Randomized phase II study of AZD6244 MEK-inhibitor with erlotinib in KRAS wild type and KRAS mutant advanced nonsmall cell lung cancer (NCT01229150). Available at: http://www.clinicaltrials.gov/ ct2/show/NCT01229 150?term=erlotinib&recr=Open&rank=28. Accessed December 3, 2012.
17. U.S. National Institutes of Health. Study of oral vinorelbine and erlotinib in non-small cell lung cancer (NCT00702182). Available at: http://www.clinicaltrials. gov/ct2/show/NCT00702182?term=erlotinib&recr =Open&rank=41. Accessed December 3, 2012.
18. U.S. National Institutes of Health. Study of erlotinib with or without investigational drug (U3-1287) in subjects with advanced non-small cell lung cancer (NCT01211483). Available at: http://www.clinicaltrials. gov/ct2/show/NCT01211483?term=erlotinib&recr =Open&rank=44. Accessed December 3, 2012.
19. U.S. National Institutes of Health. AMG 102 and erlotinib for advanced non-small cell lung cancer (NCT01233687). Available at: http://www. clinicaltrials. gov/ct2/show/NCT01233687?term=erlotinib&recr =Open&rank=52. Accessed December 3, 2012.
20. U.S. National Institutes of Health. Study of erlotinib (Tarceva®) in combination with OSI-906 in patients with advanced non-small cell lung carcinoma (NSCLC) with activating mutations of the epidermal growth factor receptor (EGFR) gene (NCT01221077). Available at: http://www.clinicaltrials.gov/ct2/show/ NCT01221077?term=erlotinib&recr=Open&rank=3. Accessed December 3, 2012.
21. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-16; PMID:10655437; http://dx.doi.org/10.1093/jnci/92. 3.205z22.
22. U.S. National Institutes of Health. Common terminology criteria for adverse events v3.0 (CTCAE). Available at: http://ctep. cancer.gov/ protocolDevelopment/electronic-applications/docs/ctcaev3.pdf. Accessed December 3, 2012.